Skip to main content
Soumya Raychaudhuri, MD, Rheumatology, Boston, MA

SoumyaRaychaudhuriMDPhD

Rheumatology Boston, MA

Professor of Medicine, Harvard Medical School. JS Coblyn and MB Brenner Distinguished Chair, Brigham & Women's Hospital

Dr. Raychaudhuri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Raychaudhuri's full profile

Already have an account?

  • Office

    Brigham Womens Hospital
    75 Francis Street PBBB3
    Boston, MA 02115
    Phone+1 617-732-5325
    Fax+1 617-525-4488

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Rheumatology, 2006 - 2010
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2004 - 2006
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 2004

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2006 - 2025
  • American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • Fellow (FACR) American College of Rheumatology

Publications & Presentations

PubMed

Journal Articles

  • High-Throughput Identification of Noncoding Functional SNPs via Type IIS Enzyme Restriction  
    Soumya Raychaudhuri, Jing Cui, Michael B Brenner, Peter A Nigrovic, Nature
  • Methods for High-Dimensonal Analysis of Cells Dissociated from Cyropreserved Synovial Tissue  
    Paul J Utz, William H Robinson, Ellen M Gravallese, Soumya Raychaudhuri, Alessandra B Pernis, Susan M Goodman, Michael B Brenner, Lionel B Ivashkiv, Brendan F Boyce, P..., BioMed Central

Other

Authored Content

  • RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis FlaresJuly 2020
  • RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis FlaresJuly 2020

Press Mentions

  • Mestag Therapeutics Launches with $11m for Fibroblast Goal
    Mestag Therapeutics Launches with $11m for Fibroblast GoalApril 30th, 2021
  • Newborn Bio Business Mestag Therapeutics Raises $11m Seed Cash
    Newborn Bio Business Mestag Therapeutics Raises $11m Seed CashApril 26th, 2021
  • Mestag Therapeutics Launches with Seed Financing of $11 Million to Develop Therapeutics Targeting Activated Fibroblast Populations Across Inflammatory Disease and Cancer
    Mestag Therapeutics Launches with Seed Financing of $11 Million to Develop Therapeutics Targeting Activated Fibroblast Populations Across Inflammatory Disease and CancerApril 20th, 2021
  • Join now to see all

Professional Memberships